Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome (Nasdaq: IMNM) has appointed Roee Shahar as Executive Vice President, Commercial. Shahar brings over 20 years of experience in launching and commercializing oncology and hematology products from his roles at Seagen, Pfizer, and Eli Lilly & Company. This appointment strengthens Immunome's team in developing targeted oncology therapies.
CEO Clay Siegall highlighted Shahar's expertise in advancing the company's portfolio, particularly AL102, a gamma secretase inhibitor in Phase 3 trials for desmoid tumors. Shahar expressed his commitment to addressing the challenges posed by desmoid tumors, which can cause debilitating pain, deformity, and life-threatening organ damage.
Prior to joining Immunome, Shahar held leadership positions at Pfizer and Seagen, managing hematology portfolios and overseeing commercial activities for products like Adcetris® and Tivdak®. He also served as Marketing Director at Eli Lilly, leading the company's largest oncology brand, Alimta®.
Immunome (Nasdaq: IMNM) ha nominato Roee Shahar come Vice Presidente Esecutivo, Commerciale. Shahar porta con sé oltre 20 anni di esperienza nel lancio e nella commercializzazione di prodotti nel campo dell'oncologia e dell'ematologia, grazie ai suoi ruoli presso Seagen, Pfizer, ed Eli Lilly & Company. Questa nomina rafforza il team di Immunome nello sviluppo di terapie oncologiche mirate.
Il CEO Clay Siegall ha sottolineato l'expertise di Shahar nell'avanzare il portafoglio dell'azienda, in particolare AL102, un inibitore della gamma secretasi attualmente in Fase 3 per i tumori desmoidi. Shahar ha espresso il suo impegno nell'affrontare le sfide poste dai tumori desmoidi, che possono causare dolore debilitante, deformità e danni agli organi che possono essere pericolosi per la vita.
Prima di unirsi a Immunome, Shahar ha ricoperto posizioni di leadership presso Pfizer e Seagen, gestendo portafogli ematologici e supervisionando attività commerciali per prodotti come Adcetris® e Tivdak®. Ha anche lavorato come Direttore Marketing presso Eli Lilly, guidando il brand oncologico più grande dell'azienda, Alimta®.
Immunome (Nasdaq: IMNM) ha designado a Roee Shahar como Vicepresidente Ejecutivo, Comercial. Shahar trae más de 20 años de experiencia en el lanzamiento y comercialización de productos en oncología y hematología a través de sus roles en Seagen, Pfizer y Eli Lilly & Company. Esta designación fortalece el equipo de Immunome en el desarrollo de terapias oncológicas dirigidas.
El CEO Clay Siegall destacó la experiencia de Shahar en la mejora del portafolio de la compañía, especialmente AL102, un inhibidor de gamma secretasa en Fase 3 para tumores desmoides. Shahar expresó su compromiso para enfrentar los desafíos que presentan los tumores desmoides, que pueden causar dolor debilitante, deformidad y daño a órganos que amenazan la vida.
Antes de unirse a Immunome, Shahar ocupó puestos de liderazgo en Pfizer y Seagen, gestionando carteras de hematología y supervisando actividades comerciales para productos como Adcetris® y Tivdak®. También se desempeñó como Director de Marketing en Eli Lilly, liderando la marca de oncología más grande de la compañía, Alimta®.
Immunome (Nasdaq: IMNM)는 Roee Shahar를 상무이사(상업 부문)로 임명했습니다. Shahar는 Seagen, Pfizer, Eli Lilly & Company에서의 역할을 통해 종양학 및 혈액학 제품의 출시 및 상용화에 대한 20년 이상의 경험을 보유하고 있습니다. 이번 임명은 Immunome의 표적 항암 치료 개발 팀을 강화합니다.
CEO Clay Siegall은 Shahar의 전문성이 특히 AL102와 관련하여 회사의 포트폴리오를 발전시키는 데 크게 기여할 것이라고 강조했습니다. AL102는 기질 종양을 위한 3상 시험 중인 감마 세크레타제 억제제입니다. Shahar는 기질 종양이 초래하는 도전 과제를 해결하겠다는 의지를 표명했으며, 이는 심각한 통증, 변형 및 생명을 위협하는 장기 손상을 유발할 수 있습니다.
Immunome에 합류하기 전에 Shahar는 Pfizer와 Seagen에서 혈액학 포트폴리오를 관리하고 Adcetris® 및 Tivdak®와 같은 제품의 상업 활동을 감독하며 리더십 직위에 있었습니다. 또한 Eli Lilly에서 마케팅 이사로 근무하며 회사의 가장 큰 종양학 브랜드인 Alimta®를 이끌었습니다.
Immunome (Nasdaq: IMNM) a nommé Roee Shahar en tant que Vice-Président Exécutif, Commercial. Shahar apporte plus de 20 ans d'expérience dans le lancement et la commercialisation de produits en oncologie et hématologie, grâce à ses rôles chez Seagen, Pfizer et Eli Lilly & Company. Cette nomination renforce l'équipe d'Immunome dans le développement de thérapies oncologiques ciblées.
Le PDG Clay Siegall a souligné l'expertise de Shahar dans l'avancement du portefeuille de l'entreprise, en particulier AL102, un inhibiteur de gamma-sécrétase actuellement en Phase 3 pour les tumeurs desmoïdes. Shahar a exprimé son engagement à relever les défis posés par les tumeurs desmoïdes, qui peuvent causer des douleurs invalidantes, des déformations et des dommages aux organes menaçant la vie.
Avant de rejoindre Immunome, Shahar a occupé des postes de direction chez Pfizer et Seagen, gérant des portefeuilles en hématologie et supervisant des activités commerciales pour des produits tels que Adcetris® et Tivdak®. Il a également été Directeur Marketing chez Eli Lilly, dirigeant la plus grande marque d'oncologie de l'entreprise, Alimta®.
Immunome (Nasdaq: IMNM) hat Roee Shahar zum Executive Vice President für den Bereich Commercial ernannt. Shahar bringt über 20 Jahre Erfahrung in der Einführung und Kommerzialisierung von Onkologie- und Hämatologieprodukten aus seinen Tätigkeiten bei Seagen, Pfizer und Eli Lilly & Company mit. Diese Ernennung stärkt das Team von Immunome bei der Entwicklung gezielter onkologischer Therapien.
CEO Clay Siegall hob Shahars Fachkenntnisse in der Weiterentwicklung des Unternehmensportfolios hervor, insbesondere von AL102, einem Gamma-Secretase-Inhibitor in Phase 3-Studien für desmoide Tumoren. Shahar erklärte sein Engagement für die Bewältigung der Herausforderungen, die mit desmoiden Tumoren verbunden sind, die erhebliche Schmerzen, Deformitäten und lebensgefährliche Organschäden verursachen können.
Vor seinem Wechsel zu Immunome hatte Shahar Führungspositionen bei Pfizer und Seagen inne, wo er Hämatologieportfolios leitete und kommerzielle Aktivitäten für Produkte wie Adcetris® und Tivdak® überwachte. Zudem war er als Marketing Director bei Eli Lilly tätig, wo er die größte Onkologie-Marke des Unternehmens, Alimta®, leitete.
- Appointment of experienced executive Roee Shahar as EVP, Commercial
- Shahar's expertise in launching and commercializing oncology products
- Strengthening of the leadership team for targeted oncology therapy development
- Ongoing Phase 3 trial for AL102 in desmoid tumors
- None.
“Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “His expertise will help us advance a portfolio of targeted oncology agents, particularly AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors.”
“I share the team’s passion to address the debilitating pain, deformity and, in some cases, life threatening organ damage caused by desmoid tumors,” said Mr. Shahar. “It is an honor to join a company that possesses the vision and courage to tackle challenges in cancer therapy that others will not.”
Prior to joining Immunome, Roee served as Vice President and Franchise Lead for Pfizer, where he managed the combined hematology portfolio resulting from the December 2023 acquisition of Seagen. Before the acquisition, he served as Vice President and Franchise Lead for Seagen, overseeing all commercial activities for hematology (Adcetris®) and cervical cancer (Tivdak®). Mr. Shahar previously served as Marketing Director and Oncology Brand Leader for Eli Lilly & Company with responsibility for the company’s largest oncology brand at the time, Alimta®.
Mr. Shahar earned his B.S. degree from the Kelley School of Business at
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “will,” “advance,” “vision,” “expected,” and similar expressions to identify these forward-looking statements. These forward-looking statements include, but are not limited to, Immunome’s expectations around Immunome’s ability to bring benefit to cancer patients with its pipeline; Immunome’s expected timeline for regulatory filings; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; Immunome’s ability to grow and successfully execute on its business plan, including the development and commercialization of its pipeline and integration of newly acquired assets; the risk that prior experience and success of Immunome’s management team is not indicative of future success; and other risks and uncertainties indicated from time to time described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008310198/en/
Immunome Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
Who is the new Executive Vice President, Commercial at Immunome (IMNM)?
What is Immunome's (IMNM) lead product candidate and its current development stage?
What is Roee Shahar's background before joining Immunome (IMNM)?
What specific products has Roee Shahar worked on in his previous roles?
